Roche Notches Big IO Win With Tecentriq/Avastin Combo In First-Line HCC
Following quickly on a Bristol trial failure with Opdivo in first-line HCC, Roche’s PD-L1 inhibitor looks poised to be the first immunotherapy approved in the setting, with plans for US, EU and China filings.
You may also be interested in...
With Phase III Failure, Exelixis Drops First-Line Liver Cancer Plans For Cabometyx
While a combo of Cabometyx and Roche’s Tecentriq earlier demonstrated a progression-free survival benefit compared to Nexavar, a subsequent readout showed no overall survival benefit.
Keeping Track: Aimmune’s Peanut Allergen Approved; Novartis’ Inclisiran, Pfizer/Lilly’s Tanezumab, Bayer’s Nifurtimox Submitted
Highlights of the latest drug development news from our US FDA Performance Tracker.
Narrow HCC CheckMate-459 Miss For Opdivo Points The Way For Combos, Roche Shows How
Full data at ESMO show Opdivo managed to scrape a tolerability edge over standard-of-care sorafenib in liver cancer, but eyes were drawn to Roche’s early study of Tecentriq/Avastin as the way forward in this difficult-to-treat cancer.